Nanologica AB (publ)
Nanologica AB (publ) is a biotechnology company focused on the development of nanotechnology-based products for the life sciences and healthcare industries, primarily generating revenue through product sales and research collaborations.
Business. Nanologica AB (publ) (NICA.ST) is a Swedish company operating in the commodity chemicals industry within the broader chemicals sector. The firm is headquartered in Sweden and is primarily listed on the Nasdaq Stockholm exchange. As specific segment and geographic breakdowns are not provided, the company is described at the industry level as a participant in the commodity chemicals market.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Nanologica AB (publ) (NICA.ST) is a Swedish company operating in the commodity chemicals industry within the broader chemicals sector. The firm is headquartered in Sweden and is primarily listed on the Nasdaq Stockholm exchange. As specific segment and geographic breakdowns are not provided, the company is described at the industry level as a participant in the commodity chemicals market.
Nanologica's capital structure is characterized by a debt-to-equity ratio of 0.95, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 1.85, suggesting it can cover short-term obligations but with limited buffer. Free cash flow is negative at -39.93 million SEK, reflecting ongoing operational cash outflows.
Profitability metrics are sharply negative, with a return on equity of -226.49% and a return on assets of -58.21%, both significantly below the industry median for Commodity Chemicals. The company reported a net loss of 51.29 million SEK and an operating loss of 46.80 million SEK, indicating a challenging operating environment.
Geographically, Nanologica's revenue is concentrated in its home market, with no disclosed international revenue segments. The company's business is entirely disclosed under a single segment, with no diversification across product lines or geographic regions.
Growth trajectory is negative, with a year-over-year revenue decline of 62.0% from 55.7 million SEK to 21.13 million SEK. Analysts project a significant revenue contraction in the next fiscal year, with a mean estimate of 83.1 million SEK, which is still below the prior year's performance.
Risk factors include liquidity constraints, with negative net cash after subtracting total debt. The company has a low dilution risk, with no near-term pressure from share issuance. However, the operating cash flow of -39.88 million SEK and free cash flow of -39.93 million SEK highlight the need for external financing or operational improvements.
Recent events include a 100% consensus among analysts for a price target of 2.97 SEK, unchanged from the previous quarter. The company's last actual EPS was -0.57 SEK, with a mean EPS estimate of 0.00 SEK for the next period, indicating no improvement in earnings is expected.
- Nanologica is operating at a significant loss, with a net income of -51.29 million SEK and a return on equity of -226.49%.
- The company's liquidity position is medium, with a current ratio of 1.85 and negative free cash flow of -39.93 million SEK.
- Revenue has declined sharply by 62.0% year-over-year, and analyst estimates suggest continued contraction.
- The company has a low dilution risk, but its operating cash flow and free cash flow are deeply negative.
- Analysts have set a uniform price target of 2.97 SEK, with no improvement in earnings expected in the near term.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Nanologica AB (publ) Market data — financials · 2026-05-28
- Nanologica AB (publ) Market data — analyst estimates · 2026-05-28